StockData
Compass Therapeutics, Inc. logo

Compass Therapeutics, Inc. (CMPX) stock

CMPXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$0.82−0.01 (-1.23%)

Close on Nov 12, 2026Market cap $147.67MP/E –Yield –

Compass Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Compass Therapeutics's operating cash flow for the twelve months ending Sep 30, 2026 was -$61.58M. For fiscal 2025 it was -$49.14M. The highest annual figure on record is -$19.67M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$49.14M–
FY2024Dec 31, 2024-$44.86M–
FY2023Dec 31, 2023-$40.62M–
FY2022Dec 31, 2022-$34.13M–
FY2021Dec 31, 2021-$19.67M–
FY2020Dec 31, 2020-$26.80M–
FY2019Dec 31, 2019-$31.74M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$16.32M–
Q2 FY2026Jun 30, 2026-$14.74M–
Q1 FY2026Mar 31, 2026-$17.27M–
Q4 FY2025Dec 31, 2025-$13.25M–
Q3 FY2025Sep 30, 2025-$10.85M–
Q2 FY2025Jun 30, 2025-$11.83M–
Q1 FY2025Mar 31, 2025-$13.21M–
Q4 FY2024Dec 31, 2024-$9.16M–
Q3 FY2024Sep 30, 2024-$11.05M–
Q2 FY2024Jun 30, 2024-$10.75M–
Q1 FY2024Mar 31, 2024-$13.89M–
Q4 FY2023Dec 31, 2023-$12.35M–
Q3 FY2023Sep 30, 2023-$5.92M–
Q2 FY2023Jun 30, 2023-$10.11M–
Q1 FY2023Mar 31, 2023-$12.23M–
Q4 FY2022Dec 31, 2022-$10.64M–
Q3 FY2022Sep 30, 2022-$10.94M–
Q2 FY2022Jun 30, 2022-$4.60M–
Q1 FY2022Mar 31, 2022-$7.94M–
Q4 FY2021Dec 31, 2021-$4.67M–
Q3 FY2021Sep 30, 2021-$3.46M–
Q2 FY2021Jun 30, 2021-$5.94M–
Q1 FY2021Mar 31, 2021-$5.61M–
Q4 FY2020Dec 31, 2020-$6.57M–
Q3 FY2020Sep 30, 2020-$7.17M–
Q2 FY2020Jun 30, 2020-$5.30M–
Q1 FY2020Mar 31, 2020-$7.76M–
Q2 FY2019Sep 30, 2019-$6.70M–
Q1 FY2019Jun 30, 2019-$19.45M–

More Compass Therapeutics figures

See a number that looks wrong?